Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

For patients with diabetes, exposure to GLP-1 RAs is associated with an increased risk for incident neovascular AMD development.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an announcement. On June 4, 2025, Biodexa Pharmaceuticals announced the recruitment of the first ...

Increased consumption of phytosterols reduced the risk for CVD and type 2 diabetes, a study presented at the annual NUTRITION ...

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ...

TUCSON, AZ / ACCESS Newswire / June 2, 2025 / Umbrella Labs , a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an ...

This recent study introduces a non–insulin-specific version of the Diabetes Eating Problem Survey–Revised tool that screens ...

Wenzhou Medical University researchers have reimagined the spleen as a viable site for islet transplantation, enabling ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.